Lexaria Bioscience Corp. (LEXX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Lexaria Bioscience Corp., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Lexaria Bioscience Corp. (LEXX) has returned 26.42% so far this year and -54.39% over the past 12 months.

Based on dividend-adjusted daily data since May 12, 2016, LEXX's average daily return is +0.15%, while the average monthly return is +2.73%. At this rate, your investment would double in approximately 2.1 years.

Historically, 38% of months were positive and 62% were negative. The best month was Feb 2024 with a return of +131.5%, while the worst month was May 2023 at -64.5%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 8 months.

On a daily basis, LEXX closed higher 44% of trading days. The best single day was Oct 17, 2016 with a return of +58.3%, while the worst single day was Jan 12, 2021 at -33.6%.

Lexaria Bioscience Corp. has an annualized alpha of 32.36%, beta of 0.74, and R² of 0.02 versus S&P 500 Index. Calculated based on daily prices since May 13, 2016.

• This stock participated in 185.99% of S&P 500 Index downside but only 92.31% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.02 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

LEXX ranks 18 for risk / return — in the bottom 18% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for Lexaria Bioscience Corp. (LEXX) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Lexaria Bioscience Corp.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Lexaria Bioscience Corp. was 99.25%, occurring on Dec 26, 2025. The portfolio has not yet recovered.

The current Lexaria Bioscience Corp. drawdown is 98.89%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Lexaria Bioscience Corp. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Lexaria Bioscience Corp. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.